CJC-1295 no DAC is growth hormone releasing hormone 1-29 with a small set of amino acid substitutions and no drug affinity complex attached. Its identity test has one main job: telling it apart from sermorelin, which weighs about ten daltons less on a 3.3 kilodalton molecule. Peptide mapping settles it by showing where each substitution sits.
- CJC-1295 no DAC is growth hormone releasing hormone 1-29 with a small set of amino acid substitutions and no drug affinity complex, weighing about 3,368 daltons.
- The identity question for CJC-1295 no DAC is closing a ten-dalton gap from sermorelin, about three parts in a thousand, and the mass figure is a deconvolution output.
- Peptide mapping localizes each substitution to a fragment rather than to a total.
- Overlapping amino acid masses mean a right total can in principle hide wrong substitutions.
- The D-configuration substitution is invisible to every mass method, including the map.
- The DAC version differs by a large appended group and is trivially excluded.
What is CJC-1295 no DAC?
CJC-1295 no DAC is growth hormone releasing hormone 1-29 with a small set of amino acid substitutions, supplied without the drug affinity complex that the DAC version carries. It is also called modified GRF 1-29, and listings write it as CJC-1295 without DAC as well. The chain is 29 residues long and weighs about 3,368 daltons.
Sermorelin is the same 29-residue frame without the substitutions. Both are sold in this market, both are white lyophilized cake, and their masses differ by about ten daltons. That closeness is why identity is the question worth a whole page for this peptide.
- Deconvoluted mass near 3367.9, stated as a number
- Sermorelin sits near 3357.9: three parts in a thousand away
- Peptide mapping localises each substitution to a fragment
- Amino acid analysis confirms composition independently
- Chiral analysis for the D residue, which no mass method can see
- The DAC version excluded trivially by intact mass
- Accession number confirmed at the issuing laboratory
CJC-1295 with DAC vs no DAC: what is the difference?
The difference is one attached group. DAC stands for drug affinity complex. CJC-1295 with DAC carries that complex, and the no DAC form is the peptide chain without it. Attaching the drug affinity complex adds a substantial chemical group, so the masses differ by a large amount where the gap from sermorelin is a subtle one.
That makes DAC vs no DAC the simple part of the analysis. Any competent intact-mass measurement separates them unambiguously. There is no realistic scenario in which a laboratory weighs the molecule and cannot tell which of the two it has.
So a mismatch between a certificate's mass and a vial labeled with DAC is a supply or labeling problem rather than an analytical uncertainty, and it should be resolved as one.
What does a CJC-1295 no DAC identity test need to show?
It needs to show that the vial holds this analog and not the parent it was modified from. Showing a peptide of roughly the right size falls short of that.
Weighing the molecule against its close relatives barely helps, because they differ by only a few changed letters in the same 29-residue chain. Imagine telling nearly identical twins apart: you have to check the specific spots where they differ, and that is what peptide mapping does.
So the identity question is narrow and specific. Most of this page is about closing a ten-dalton gap on a molecule of about 3,368.
Why is intact mass a weak instrument here?
Intact mass is weak here because of how the measurement is made. A molecule this size picks up several protons in electrospray, so the instrument records a family of charge states rather than one peak, and software combines that envelope into a single figure by deconvolution.
The number on the certificate is therefore the output of a calculation, carrying the tolerance of that calculation.
Ten daltons on 3,368 is roughly three parts in a thousand. That is within reach of a well-run measurement and it is not a comfortable margin, and it is nothing like the unambiguous separation the same ten daltons would give on a 700-dalton peptide. The gap is real; the instrument is poorly matched to it.
What does peptide mapping do that mass cannot?
Peptide mapping localizes. The peptide is cut at defined points by a specific enzyme, producing a set of fragments, and each fragment is weighed separately.
A substitution changes the mass of whichever fragment contains it. So instead of one ten-dalton difference spread across a 3,368-dalton total, you get a much larger proportional difference on a small fragment, and it is attached to a position rather than floating free in the sum.
That is the difference between knowing the molecule weighs about ten more than sermorelin and knowing that residue two, residue eight, residue fifteen and residue twenty-seven are what they should be. Only the second is an identity claim about this analog.
Why does localization matter and not just the total?
Localization matters because several different substitution patterns can produce a similar total. Amino acids have overlapping masses, so swapping one residue for another elsewhere in the chain can partly offset a difference and leave the sum looking plausible.
A peptide with the right total mass and the wrong substitutions is not this compound. It would pass an intact-mass check and fail a map.
Such a failure is uncommon commercially, and it is the reason the analytical hierarchy exists. Mass constrains; mapping identifies. A certificate offering only the first has told you the molecule is about the right size and has not told you it is the right molecule.
What about the D-configuration substitution?
The D-configuration substitution is invisible to every mass-based method, including the map. One of the modifications places a residue in the D configuration rather than the L form found in natural sequences.
A D-amino acid and its L counterpart are mirror images containing identical atoms connected in an identical order. They weigh exactly the same, so no mass measurement at any resolution separates them, and a fragment containing one weighs the same as a fragment containing the other.
Only chiral analysis answers it, usually by hydrolyzing the peptide and separating the freed amino acids on a handed stationary phase. It is absent from most research certificates, which is a limit rather than a scandal and worth knowing before assuming a mass result covered everything.
Does the separation help distinguish CJC-1295 without DAC from sermorelin?
Sometimes it does, though too unreliably to depend on. Substituting residues changes hydrophobicity slightly, so this analog and sermorelin usually elute at somewhat different times on a reversed-phase column.
Whether they resolve depends entirely on the method. A gradient developed to check purity of one compound is not necessarily a gradient that separates it from a near neighbor, and nothing about the chromatogram announces which situation you are in.
Used deliberately, with both compounds run as references, retention is useful supporting evidence. Used incidentally, it proves very little, which is the general problem with retention time stated as an identity result.
What are deletion sequences and how are they found?
Deletion sequences are the characteristic impurity of stepwise synthesis. A 29-residue chain takes 28 coupling steps, and a step that fails on a fraction of chains produces molecules missing exactly one residue.
Each differs from the target by one amino acid mass, roughly 57 to 186 daltons. That is detectable, and such species are nearly the same molecule so they frequently elute very close to the target.
Resolution matters more than sensitivity here. A separation not developed to pull deletions away from the main peak counts them inside it, and the reported purity flatters the material. Peptide mapping catches them too, since a deletion changes the fragment containing it.
What does amino acid analysis contribute?
Amino acid analysis contributes composition, measured independently of both the separation and the mass. The peptide is hydrolyzed to its constituent residues and each is quantified, giving the ratio present.
For an analog defined by substitutions that is directly relevant, because changing residues changes the composition. A sequence with an extra alanine and one fewer of something else has a different amino acid ratio from the parent.
It also produces a peptide content figure by weight that does not depend on chromatographic assumptions, which is the honest answer to how much peptide is in the vial and why net peptide content is reported separately from area purity.
How do you check the report describes your vial, step by step?
- Confirm the accession or verification number at the issuing laboratory rather than with the seller. The laboratory holds the record; a seller holds a copy of a document.
- If the number resolves to a different lot, a different product, or nothing, treat the analysis as no evidence about your material.
- Match the lot number on the report to the vial. Rigorous analysis attached to the wrong batch counts for little, and for a compound with a ten-dalton neighbor that mismatch is more consequential than usual.
Reports for material supplied here resolve through the certificate verification page, and the sizes carried appear on the CJC-1295 no DAC product record.
What should you ask a supplier about identity?
Three questions, and the second is the one that matters:
- What was the deconvoluted mass, as a number?
- Was any sequence-level work done, meaning peptide mapping or amino acid analysis?
- Does the accession number resolve at the issuing laboratory?
A supplier answering only the first has established that the material weighs roughly what this analog weighs, which is also roughly what sermorelin weighs. For two products separated by ten daltons that is not a satisfying answer.
How to read the rest of the document is covered in the certificate guide.
What is the regulatory position?
International guidance on analytical validation defines what makes an identity method fit for purpose: specificity, accuracy, precision, and a demonstration that the method distinguishes the target from what else might plausibly be present. Sermorelin is exactly what is plausibly present here, and that is the clause an intact mass struggles with.
There is no FDA-approved product containing this compound and no United States pharmacopeial monograph, so no official standard defines what may be sold under this name. The specification is the supplier's own.
What a research certificate can honestly establish is what a named laboratory measured, on a named lot, by named methods.
FOR LABORATORY AND IN-VITRO RESEARCH USE ONLY. NOT FOR HUMAN OR ANIMAL CONSUMPTION. NOT FOR PERSONAL, MEDICAL, DIAGNOSTIC, THERAPEUTIC, OR RECREATIONAL USE.
Bottom line
CJC-1295 no DAC sits about ten daltons from sermorelin, so intact mass alone is a weak identity result. Look for peptide mapping or amino acid analysis on the certificate, remember that the D-configuration residue needs chiral analysis, and confirm the accession number and lot at the issuing laboratory. The DAC version is the easy case, separated by a large mass difference.
What is CJC-1295 (no DAC) studied for?
Published research on CJC-1295 (no DAC) investigates the areas below, which is a different question from what CJC-1295 (no DAC) will do for anyone, a claim about a living system that nothing on this site is sold for.
What it is. A man-made 29-building-block copy of GHRH, also sold under the name Mod GRF(1-29).
What the research looks at. It appears in research on the GHRH receptor. The history of those four swaps is well documented and reads as an honest list of the ways the original sequence falls apart.
How it is thought to work. It works on the GHRH receptor. Four building blocks are swapped out at positions 2, 8, 15 and 27. Two of those swaps are repairs: one replaces a building block that tends to break down, the other replaces one that tends to react with oxygen.
What is not established. No approved product. The with-DAC and no-DAC versions are chemically different molecules with different handling needs and must not be treated as the same thing. This record is about the no-DAC form.
The full record, including the certificate for the lot in stock, is on the CJC-1295 (no DAC) product page.
Common questions
What is CJC-1295 no DAC?
What is DAC in CJC-1295?
How is CJC-1295 no DAC identity tested?
Why is intact mass weak evidence for this compound?
What does peptide mapping add?
Could a peptide have the right mass and the wrong substitutions?
Can any mass method confirm the D-amino acid?
How is CJC-1295 with DAC excluded?
Published certificates for CJC-1295 (no DAC)
Every figure below is read from a report the laboratory issued for that lot; each page carries the PDF and the lab's own verification link.
More documentation guides
Sources
- PubChem Compound Summary for CID 16132413, Sermorelin. The openable record for the unmodified GHRH 1-29 parent, giving the average mass near 3357.9 against which this analogue's figure of about 3367.9 must be distinguished.
- UniProt P01286, Somatoliberin (growth hormone-releasing hormone). The reference protein record for human GHRH, whose first 29 residues form the frame both this analogue and sermorelin are built on.
- ICH Q2(R2), Validation of Analytical Procedures . Defines specificity, including that a method must distinguish the target from closely related substances. Sermorelin is precisely the closely related substance in this case.
- FDA guidance, Q6B Specifications: Test Procedures and Acceptance Criteria. Sets out peptide mapping and amino acid analysis among the identity tests expected for larger molecules, alongside rather than instead of intact mass.

